Dr. Samuel Rosner, a thoracic oncologist at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, said a growing number of people, particularly women under 65, are ...

It started with a dull ache in my right shoulder. At first, I chalked it up to bad posture or sleeping funny. Then came a ...

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Zai Lab Limited ( NASDAQ: ZLAB) said on Monday that it received U.S. FDA fast track designation for its antibody-drug ...

Eligible patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and ...

"While the overall survival rates for patients with non-small cell lung cancer have significantly improved in recent years, lung cancer continues to be the leading cause of cancer death worldwide ...

The antibody-drug conjugate (ADC) is currently under review by the FDA as a treatment for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adults who have undergone prior ...

As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Cemiplimab with chemotherapy for untreated advanced or metastatic ...